The bill amends various sections of the Idaho Code concerning controlled substances, focusing on the classifications of drugs from Schedule I to Schedule V. It introduces several new substances into Schedule I, including various fentanyl analogs and synthetic opioids such as Beta-methylacetyl fentanyl and Brorphine, reflecting their high potential for abuse and lack of accepted medical use. Additionally, the bill updates the classifications of other drugs, adding substances like Bromazolam and Clonazolam while removing certain compounds such as N-ethylpentylone and PeGACLONE. The bill also modifies the definitions of synthetic drugs and their analogs, ensuring that new compounds derived from existing structures are included in the controlled substances list.

Moreover, the bill revises registration requirements for individuals and entities involved in the manufacture, distribution, or prescription of controlled substances, changing the registration period from annually to biennially. It establishes a controlled substances prescriptions database, detailing access protocols and penalties for misuse. The bill emphasizes the importance of maintaining effective controls against the diversion of controlled substances and outlines disciplinary actions for registrants who violate regulations. With an emergency declaration, the act is set to take effect on July 1, 2026, aiming to enhance public safety and address the evolving landscape of substance use and abuse in Idaho.

Statutes affected:
Bill Text: 37-2705, 37-2707, 37-2709, 37-2711, 37-2713, 37-2716, 37-2717, 37-2718, 37-2719, 37-2720, 37-2722, 37-2726, 37-2731